<i>FLT3</i> inhibitors, including midostaurin, gilteritinib, and quizartinib, have improved survival in <i>FLT3</i>-mutated AML, while emerging evidence supports potential benefit in selected <i>FLT3</i>-wild-type disease based on <i>FLT3</i>-like gene expression signatures. Here, FLT3 is linked to acute myeloid leukemia.